Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) shares traded down 6.7% on Monday . The company traded as low as $9.54 and last traded at $9.54. 61,636 shares traded hands during mid-day trading, an increase of 74% from the average session volume of 35,474 shares. The stock had previously closed at $10.22.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of Greenwich LifeSciences in a report on Tuesday, February 11th.
Read Our Latest Stock Report on GLSI
Greenwich LifeSciences Stock Performance
The firm's 50-day moving average price is $11.81 and its two-hundred day moving average price is $12.84. The firm has a market cap of $116.66 million, a PE ratio of -11.09 and a beta of 1.76.
Insider Buying and Selling at Greenwich LifeSciences
In other Greenwich LifeSciences news, CEO Snehal Patel acquired 2,500 shares of the stock in a transaction on Friday, January 10th. The shares were bought at an average price of $12.51 per share, with a total value of $31,275.00. Following the acquisition, the chief executive officer now owns 5,552,502 shares of the company's stock, valued at $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 51.67% of the company's stock.
Institutional Trading of Greenwich LifeSciences
Several hedge funds have recently modified their holdings of GLSI. Wells Fargo & Company MN raised its position in Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock worth $32,000 after acquiring an additional 1,008 shares in the last quarter. Barclays PLC increased its holdings in shares of Greenwich LifeSciences by 12.7% in the 4th quarter. Barclays PLC now owns 9,648 shares of the company's stock valued at $108,000 after purchasing an additional 1,088 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after purchasing an additional 1,322 shares during the period. State Street Corp boosted its holdings in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company's stock worth $1,026,000 after buying an additional 3,005 shares in the last quarter. Finally, Brown Brothers Harriman & Co. acquired a new position in Greenwich LifeSciences during the fourth quarter worth about $45,000. 4.16% of the stock is owned by institutional investors and hedge funds.
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Articles
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
